Alnylam Pharmaceuticals, Inc. Share Price & Technical Analysis
ALNY · $297.5 (-1.02%)
Healthcare / Biotechnology
$297.5
-1.02%
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute he…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-4% return in May, 5% avg return in past 3 year May month.
-27% return in 2026, 27% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -15% | -1% | 0% | -7% | -4% | – | – | – | – | – | – | – | -27% |
| 25 | 14% | -9% | 10% | -3% | 18% | 8% | 21% | 15% | 2% | 0% | -1% | -12% | 63% |
| 24 | -9% | -13% | -1% | -3% | 3% | 63% | -1% | 5% | 6% | -3% | -5% | -7% | 34% |
| 23 | -5% | -16% | 5% | 0% | -7% | 2% | 4% | 2% | -11% | -14% | 11% | 14% | -15% |
| 22 | -20% | 14% | 3% | -20% | -4% | 16% | -2% | 46% | -3% | 1% | 5% | 8% | 44% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$39.24B
P/E ratio
73.67
52W high
$495.6
52W low
$284.3
Volume
6,81,308
Beta
0.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Alnylam Pharmaceuticals, Inc. share price today?
- Alnylam Pharmaceuticals, Inc. (ALNY) last traded around $297.5 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALNY have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALNY. Download the app for real-time alerts.
- How can I analyze Alnylam Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.